Assessment of the state of the cardiovascular system in young and middle-age military men depending on the level of blood serum uric acid

Abstract

BACKGROUND: The prevalence of asymptomatic hyperuricemia is about 10%. It is a frequent companion of cardiorenometabolic diseases. Hyperuricemia contributes to systemic inflammation, leads to endothelial dysfunction and impaired renal function. An increase in blood pressure occurs due the to the activation of the renin-angiotensin-aldosterno system in hyperurecemia. The level of uric acid more than 360 µmol/l in women and more than 420 µmol/l in men serves as an unfavorable prognosis factor. Increased attention is needed to monitoring uric acid, especially in those with multiple risk factors for the development of cardiovascular disease.

AIM: to study clinical, laboratory and instrumental indicators of the cardiovascular system in men with normouricemia and hyperuricemia to improve prevention.

MATERIALS AND METHODS: The clinic analyzed the case histories of 355 patients aged 30 to 50 years. All examined, depending on the level of blood uric acid, were divided into 4 groups: the 1^st group (58 people) — 299 µmol/l, the 2^nd (104 people) — 300–359 µmol/l, the 3^rd (104 people) 360–419 µmol/l and the 4^th (89 people) — 420 µmol/l. Clinical, laboratory and instrumental indicators of cardiovascular system, physical performance and hemodynamic response to physical activity according to bicycle ergometry were studied.

RESULTS: It has been established that hyperuricemia is associated with an increase in office and daily BP parameters, an increase in heart rate, R wave amplitude in the AVL lead on the ECG, glycemia, lipidemia, SCORE risk, relative left ventricular wall thickness and left atrial size, and left ventricular diastolic function. The total amount of exercise performed, maximum heart rate and exercise tolerance in people with normal uricemia significantly exceed those in patients with hyperuricemia, and the initial heart rate and peak and blood pressure in the recovery period are significantly higher with hyperuricemia, compared with men with normouricemia.

Keywords

arterial hypertension / asymptomatic hyperuricemia / bicycle ergometry / cardiovascular system / male gender / purine metabolism / young and middle age

References

[1] Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7–122. (In Russ.) DOI:10.15829/1560-4071-2018-6-7-122

[2] Кардиоваскулярная профилактика 2017. Российские национальные рекомендации // Российский кардиологический журнал. 2018. Т. 23, № 6. С. 7–122. DOI:10.15829/1560-4071-2018-6-7-122

[3] Benjamin E, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association. Circulation. 2019;139(10): e56–e528. DOI: 10.1161/cir.0000000000000659

[4] Benjamin E., Muntner P., Alonso A., et al. Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association // Circulation. 2019. Vol. 139, No. 10. P. e56–e528. DOI: 10.1161/cir.0000000000000659

[5] Piepoli M, Hoes A, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. DOI:10.1093/eurheartj/ehw106

[6] Piepoli M., Hoes A., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) // Eur. Heart J. 2016. Vol. 37, No. 29. P. 2315–2381. DOI:10.1093/eurheartj/ehw106

[7] Ametov AS, Pashkova EYu, Ramazanova ZD, et al. Obesity as a non-infectious epidemic of the XXI century. Modern ideas about the pathogenesis, risks and approaches to pharmacotherapy. Endocrinology: News, Opinions, Training. 2019;8(2):57–66. (In Russ.) DOI: 10.24411/2304-9529-2019-12007

[8] Аметов А.С., Пашкова Е.Ю., Рамазанова З.Д., и др. Ожирение как неинфекционная эпидемия XXI века. Современные представления о патогенезе, рисках и подходах к фармакотерапии // Эндокринология: новости, мнения, обучение. 2019. Т. 8, № 2. С. 57–66. DOI: 10.24411/2304-9529-2019-12007

[9] Gordienko AV, Mirokhina MA, Dydyshko VT, et al. Metabolic disturbances in the future development and progression of arterial hypertension in young men. The Clinician. 2015;9(2):23–27. (In Russ.) DOI: 10.17650/1818-8338-2015-9-2-23-27

[10] Гордиенко А.В., Мирохина М.А., Дыдышко В.Т., и др. Метаболические нарушения в перспективе развития и прогрессирования артериальной гипертензии у молодых мужчин // Клиницист. 2015. Т. 9, № 2. С. 23–27. DOI: 10.17650/1818-8338-2015-9-2-23-27

[11] Gordienko AV, Serdyukov DYu. Initial atherosclerosis: risk factors, diagnosis, prevention, treatment. Saint Petersburg: SpetsLit Publisher; 2020;119 p. (In Russ.)

[12] Гордиенко А.В., Сердюков Д.Ю. Начальный атеросклероз: факторы риска, диагностика, профилактика, лечение. СПб.: СпецЛит, 2020. 119 с.

[13] Serdyukov DYu. Preclinical diagnosis of atherosclerosis at a young age. Medline.ru. Russian biomedical journal. 2018;19:693–704. (In Russ.)

[14] Сердюков Д.Ю. Доклиническая диагностика атеросклероза в молодом возрасте // Medline.ru. Российский биомедицинский журнал. 2018. Т. 19. С. 693–704.

[15] Shal’nova SA, Deev AD, Artamonov GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2): 153–159. (In Russ.) DOI: 10.20996/1819-6446-2014-10-2-153-159

[16] Шальнова С.А., Деев А.Д., Артамонов Г.В., и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ) // Рациональная фармакотерапия в кардиологии. 2014. Т. 10, № 2. С. 153–159. DOI: 10.20996/1819-6446-2014-10-2-153-159

[17] Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) DOI: 10.15829/1560-4071-2020-3-3786

[18] Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Клинические рекомендации «Артериальная гипертензия у взрослых» // Российский кардиологический журнал. 2020. Т. 25, № 3. С. 149–218. DOI: 10.15829/1560-4071-2020-3-3786

[19] Muiesan M, Agabiti-Rosei C, Paini A, Salvetti M. Uric acid and cardiovascular disease: an update. Eur Cardiol. 2016;11(1):54–59. DOI: 10.15420/ecr.2016:4:2

[20] Muiesan M., Agabiti-Rosei C., Paini A., Salvetti M. Uric acid and cardiovascular disease: an update // Eur. Cardiol. 2016. Vol. 11, Nо. 1. P. 54–59. DOI: 10.15420/ecr.2016:4:2

[21] Shahin L, Patel K, Heydari M, et al. Hyperuricemia and Cardiovascular Risk. Cureus. 2021;13(5): e14855. DOI: 10.7759/cureus.14855

[22] Shahin L., Patel K., Heydari M., et al. Hyperuricemia and Cardiovascular Risk // Cureus. 2021. Vol. 13, No. 5. P. e14855. DOI: 10.7759/cureus.14855

[23] Kryukov EV, Makeeva TG, Potekhin NP, et al. Prevention of vascular wall remodeling in individuals with prehypertension. Military Medical Journal. 2020;341(5):82–85. (In Russ.) DOI: 10.17816/RMMJ82310

[24] Крюков Е.В., Макеева Т.Г., Потехин Н.П. и др. Профилактика ремоделирования сосудистой стенки у лиц с предгипертонией // Военно-медицинский журнал. 2020. Т. 341, № 5. С. 82–85. DOI: 10.17816/RMMJ82310

[25] Babyuk AE, Dydyshko VT. Hyperuricemia and assessment of the cardiovascular system state in military servicemen of the young and middle age. Russian Military Medical Academy Reports. 2021;40(S1–3): 27–32. (In Russ.)

[26] Бабюк А.Э., Дыдышко В.Т. Гиперурикемия и оценка состояния сердечно-сосудистой системы у военнослужащих-мужчин молодого и среднего возраста // Известия Российской Военно-медицинской академии. 2021. Т. 40, № S1–3. С. 27–32.

[27] Serdyukov DYu. General and additional cardiovascular risk markers in the soldier-men of young and average age with initial atherosclerotic changes in the vascular wall. Pacific Medical Journal. 2017;68(2): 46–50. (In Russ.) DOI: 10.17238/PmJ1609-1175.2017.2.46-50.

[28] Сердюков Д.Ю. Основные и дополнительные маркеры риска сердечно-сосудистых заболеваний у военнослужащих-мужчин молодого и среднего возраста с начальными атеросклеротическими изменениями сосудистой стенки // Тихоокеанский медицинский журнал. 2017. Т. 68, № 2. С. 46–49. DOI: 10.17238/PmJ1609-1175.2017.2.46-50

[29] Barsukov AV. Febuxostat in the treatment of hyperuricemia: focus on cardiovascular safety. Clinical Pathophysiology. 2021;27(4):21–26. (In Russ.)

[30] Барсуков А.В. Фебуксостат в терапии гиперурикемии: фокус на кардиоваскулярную безопасность // Клиническая патофизиология. 2021. Т. 27, № 4. С. 21–26.

[31] FitzGerald J, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res. (Hoboken). 2020;72(6):744–760. DOI: 10.1002/acr.24180

[32] FitzGerald J., Dalbeth N., Mikuls T., et al. 2020 American College of Rheumatology Guideline for the Management of Gout // Arthritis. Care Res. (Hoboken). 2020. Vol. 72, No. 6. P. 744–760. DOI: 10.1002/acr.24180

[33] Pérez Ruiz F, Richette P, Stack A, et al. Failure to reach uric acid target of < 0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2): e001015. DOI: 10.1136/rmdopen-2019-001015

[34] Pérez Ruiz F., Richette P., Stack A., et al. Failure to reach uric acid target of < 0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality // RMD Open. 2019. Vol. 5, No. 2. P. e001015. DOI: 10.1136/rmdopen-2019-001015

[35] Borghi C, Rosei E, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9): 1729–1741. DOI: 10.1097/HJH.0000000000000701

[36] Borghi C., Rosei E., Bardin T., et al. Serum uric acid and the risk of cardiovascular and renal disease // J. Hypertens. 2015. Vol. 33, No. 9. P. 1729–1741. DOI: 10.1097/HJH.0000000000000701

[37] Rincon-Choles H, Jolly S, Arrigain S, et al. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol. 2017;46(4): 315–322. DOI: 10.1159/000481460

[38] Rincon-Choles H., Jolly S., Arrigain S., et al. Impact of Uric Acid Levels on Kidney Disease Progression // Am. J. Nephrol. 2017. Vol. 46, No. 4. P. 315–322. DOI: 10.1159/000481460

[39] Yu S, Yang H, Guo X, et al. Hyperuricemia is independently associated with left ventricular hypertrophy in post-menopausal women but not in pre-menopausal women in rural Northeast China. Gynecol Endocrinol. 2015;31(9):736–741. DOI: 10.3109/09513590.2015.1056730

[40] Yu S., Yang H., Guo X., et al. Hyperuricemia is independently associated with left ventricular hypertrophy in post-menopausal women but not in pre-menopausal women in rural Northeast China // Gynecol. Endocrinol. 2015. Vol. 31, No. 9. P. 736–741. DOI: 10.3109/09513590.2015.1056730

RIGHTS & PERMISSIONS

Shapoval D.S., Dydyshko V. .